Atrium doses first patient in Corventis trial of ATR 1072 for PRKAG2 syndrome
Atrium Therapeutics announced dosing of the first patient in its Phase 1/2 Corventis trial, the first interventional study for people with PRKAG2 syndrome.
Atrium Therapeutics' only item of the week concerns its lead cardiac RNA program.
- Atrium Therapeutics announced that the first patient has been dosed in the Phase 1/2 Corventis clinical trial evaluating ATR 1072, its lead investigational therapy for the potential treatment of PRKAG2 syndrome.1 The trial is an open-label, multicenter study evaluating safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ATR 1072, enrolling approximately 37 participants across a multiple ascending dose part and a single-arm expansion cohort at the recommended Phase 2 dose.1 The company expects to report initial proof-of-concept data from Corventis in the second half of 2027.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.